At the end of the latest market close, Arcutis Biotherapeutics Inc. (ARQT) was valued at $18.49. In that particular session, Stock kicked-off at the price of $18.14 while reaching the peak value of $19.31 and lowest value recorded on the day was $18.001. The stock current value is $19.23.Recently in News on September 20, 2022, Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis. Roflumilast cream showed higher efficacy compared to vehicle in both Phase 3 studies on the primary efficacy endpoint of Investigator Global Assessment (IGA) success, with 40% of roflumilast cream treated patients achieving IGA success at eight weeks. You can read further details here
Arcutis Biotherapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $27.40 on 08/31/22, with the lowest value was $13.59 for the same time period, recorded on 01/28/22.
Arcutis Biotherapeutics Inc. (ARQT) full year performance was -12.03%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Arcutis Biotherapeutics Inc. shares are logging -29.82% during the 52-week period from high price, and 41.50% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $13.59 and $27.40.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 831721 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Arcutis Biotherapeutics Inc. (ARQT) recorded performance in the market was -7.28%, having the revenues showcasing -10.18% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.21B, as it employees total of 147 workers.
The Analysts eye on Arcutis Biotherapeutics Inc. (ARQT)
During the last month, 7 analysts gave the Arcutis Biotherapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 22.01, with a change in the price was noted -0.54. In a similar fashion, Arcutis Biotherapeutics Inc. posted a movement of -2.73% for the period of last 100 days, recording 567,160 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ARQT is recording 0.37 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.37.
Technical rundown of Arcutis Biotherapeutics Inc. (ARQT)
Raw Stochastic average of Arcutis Biotherapeutics Inc. in the period of last 50 days is set at 21.37%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 21.37%. In the last 20 days, the company’s Stochastic %K was 14.57% and its Stochastic %D was recorded 9.10%.
Considering, the past performance of Arcutis Biotherapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -7.28%. Additionally, trading for the stock in the period of the last six months notably improved by 16.62%, alongside a downfall of -12.03% for the period of the last 12 months. The shares increased approximately by -5.92% in the 7-day charts and went up by -25.12% in the period of the last 30 days. Common stock shares were lifted by -10.18% during last recorded quarter.